ARTICLE | Financial News
Cue Biopharma launches, reveals funding
January 25, 2017 1:11 AM UTC
Cancer immunotherapy company Cue Biopharma Inc. (Cambridge, Mass.) launched Tuesday and announced the close of a $16.4 million round led by MDB Capital Group. The company is developing modular biologics that join a T cell costimulatory signaling molecule with a T cell receptor (TCR) targeting complex.
The company hopes to begin clinical trials in 1H18 of its lead candidate, CUE-101. It is developing the compound to treat cervical, anal, and head and neck cancers. CUE-101 links an IL-2 costimulatory factor with a TCR targeting E6 transforming protein (human papillomavirus-18; HpV18gp1)...